Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C... Show more
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and sells medicines for serious and life-threatening diseases. Investors follow GILD because it has built a dominant position in antiviral medicine, particularly HIV treatment and prevention, while working to diversify into oncology and other therapeutic areas. The company is frequently cited as a leading example of a business whose financial profile has been shaped by a handful of highly successful products, paired with an active pipeline of investigational therapies.
Gilead Sciences was founded on June 22, 1987, by Michael L. Riordan and is headquartered in Foster City, California. The company went public in 1992 and is listed on the Nasdaq under the ticker GILD. Daniel P. O'Day has served as Chairman and Chief Executive Officer since 2019.
The company's business model centers on discovering, developing, and commercializing medications in areas of high unmet medical need. Its primary areas of focus include HIV and AIDS, viral hepatitis and other liver diseases, hematology and oncology, and inflammatory and respiratory diseases.
Gilead's product portfolio is anchored by its HIV franchise. Biktarvy, a once-daily single-tablet regimen, is the company's top-selling product. Other HIV products include Descovy, Genvoya, Odefsey, Truvada, and the longer-acting Sunlenca. In liver disease, the company markets treatments such as Epclusa, Harvoni, Vemlidy, and Viread, which are used to treat hepatitis B and hepatitis C.
The company also operates in oncology, largely through its cell therapy subsidiary Kite, which it acquired in 2017. Kite's products include Yescarta and Tecartus, which are chimeric antigen receptor (CAR) T-cell therapies used to treat certain blood cancers. Gilead's oncology portfolio also includes Trodelvy, an antibody-drug conjugate (ADC) acquired through its 2020 purchase of Immunomedics. Veklury (remdesivir) is the company's antiviral developed for the treatment of COVID-19.
Gilead's revenue is generated primarily from product sales across these therapeutic areas, with HIV products representing the largest share. The company also earns royalties, contract, and other revenues. Its competitive position rests on deep expertise in virology, a well-established HIV treatment and prevention business, and a growing presence in oncology and cell therapy.
Investors pay attention to GILD largely because of its leadership in HIV, a market where its medicines have become standard-of-care options. Biktarvy's scale provides a stable revenue base, while newer prevention products, including injectable options, have expanded the company's addressable market beyond treatment into pre-exposure prophylaxis, or PrEP, which is the use of medication to prevent HIV infection in high-risk individuals.
The company has also pursued a deliberate diversification strategy. Through acquisitions such as Kite Pharma, Immunomedics, and Forty Seven, Gilead has built a meaningful oncology business spanning CAR T-cell therapies and antibody-drug conjugates. This diversification is intended to reduce reliance on any single product and to position the company for long-term growth in cancer and inflammatory diseases.
From a financial standpoint, Gilead has historically generated substantial cash flow, supported by strong product margins typical of branded biopharmaceuticals. The company has used this financial capacity for acquisitions, partnerships, dividends, and share repurchases. Investors also monitor its research pipeline, which includes investigational long-acting HIV treatments and additional oncology programs that could become future sources of growth.
Several factors are important to understand before evaluating GILD. The company's revenue remains concentrated in its HIV portfolio, and Biktarvy in particular accounts for a large portion of total sales. A decline in demand, increased competition, or pricing pressure in this segment could have a significant financial impact.
Like all biopharmaceutical companies, Gilead faces regulatory risk, including the possibility that clinical trials fail or that regulators delay or reject product approvals. Drug development is expensive and uncertain, and not every investigational therapy will reach the market.
The company is also exposed to patent expirations and generic or biosimilar competition. As key products lose exclusivity over time, competitors may introduce lower-cost alternatives, which can reduce revenue. Gilead's oncology and cell therapy businesses face competitive pressure from other drugmakers and evolving treatment standards, while reimbursement policies and government pricing reforms can affect realized prices across the industry.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to discover ideas that match their own investment strategies. Explore the AI Screener to build a watchlist tailored to your approach.
Gilead Sciences is a prominent biopharmaceutical company whose market position has been built on decades of leadership in antiviral medicine, particularly HIV and viral hepatitis. While its HIV franchise remains central to its financial profile, the company has expanded into oncology and other areas through strategic acquisitions and internal research. For investors, GILD offers a case study in how a product-focused drugmaker balances a mature, cash-generating franchise with an evolving pipeline aimed at future growth.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor